Summary: Alcohol Use Disorder (AUD) is increasingly recognized as a complex, systemic illness rather than merely a behavioral issue. Chronic alcohol exposure disrupts the brain’s neuroimmune system, triggering cells to release inflammatory signals that reshape neural circuits and undermine the brain’s natural inhibitory controls.
A new translational study from Scripps Research shows that an FDA-approved anti-inflammatory antibody—originally used to treat rheumatoid arthritis—can sharply reduce compulsive drinking in an animal model of AUD. The therapy blocks interleukin-6 (IL-6), a pro-inflammatory molecule that rises with heavy drinking and weakens the central amygdala’s GABAergic “brake.” Restoring that inhibition lowered alcohol intake in dependent female mice and, together with postmortem human brain analyses, highlights a promising, sex-specific path for addiction treatment.
Key Facts
- The Amygdala Brake Failure: Chronic alcohol use raises IL-6 signaling in the central amygdala. This inflammation suppresses the region’s GABA system—the primary inhibitory mechanism that prevents runaway neuronal activity.
- Neural Over-Excitation: When IL-6 impairs GABAergic inhibition, neurons become over-excited. This loss of inhibitory control underlies core features of addiction: compulsive drinking, intense craving, and severe withdrawal.
- Repurposing an Autoimmune Therapy: Researchers used an antibody that blocks the IL-6 receptor—the same therapeutic class used in severe rheumatoid arthritis—to prevent IL-6 from acting on brain tissue. Treated alcohol-dependent female mice showed a marked reduction in alcohol consumption.
- Sex-Specific Response: The IL-6 receptor antibody lowered drinking in dependent female mice but not in dependent males. This divergence matches clinical patterns in which females are more vulnerable to autoimmune and inflammatory dysregulation.
- Human Tissue Confirmation: Analysis of postmortem brains from 30 individuals with AUD and 30 controls identified 377 genes with altered expression. IL-6 and other inflammation-associated genes were among the most elevated signals in the AUD group.
- Shifting the View of AUD: Framing AUD as a neuroimmune, whole-body disease reframes excessive drinking away from moral stigma and toward biologically informed, treatable medical care.
Source: Scripps Research Institute
The same drugs used to treat rheumatoid arthritis may offer a new way to curb compulsive drinking. A Scripps Research study demonstrates that an IL-6–blocking antibody, already approved by the U.S. Food and Drug Administration for some autoimmune conditions, reduces heavy alcohol consumption in alcohol-dependent female mice.
Published in the Journal of Neuroinflammation on May 22, 2026, these findings add to a growing body of evidence linking brain inflammation and immune signaling to Alcohol Use Disorder.
“AUD is, in part, driven by damage to the neuroimmune system,” says senior author Marisa Roberto, professor of translational medicine at Scripps Research. “Targeting that system could open new clinical options in the coming years.”
The study focuses on interleukin-6 (IL-6), a cytokine produced in response to stress, infection, and injury. IL-6 is well known for its role in inflammatory conditions like rheumatoid arthritis, and it is produced not only by immune cells in the body but also by cells within the brain, where it can directly affect circuit function.
Prior research linked heavy drinking to elevated blood IL-6 and identified genetic variants in the IL-6 gene associated with AUD risk. Building on these associations, Roberto’s team tested whether blocking IL-6 signaling could alter drinking behavior in a validated mouse model of alcohol dependence characterized by escalating, compulsive alcohol intake.
The researchers confirmed that chronic alcohol exposure increases IL-6 signaling in the central amygdala, a region central to emotional processing and addiction. In dependent mice, IL-6 reduced GABAergic transmission in the central amygdala. GABA normally acts as a neural brake, and weakening that brake produces the over-excitation that fuels craving and relapse.
When alcohol-dependent mice received an antibody targeting the IL-6 receptor—the same drug class used in autoimmune care—female mice consumed significantly less alcohol. Male dependent mice, and non-dependent animals of either sex, did not show a comparable reduction, suggesting the treatment acts on a specific dysregulated neuroimmune pathway driving drinking in females.
“GABA is the brain’s brake signal,” explains co-first author Chloe Erikson. “When IL-6 weakens that brake, the resulting over-excitation contributes directly to the behaviors we see in AUD: persistent drinking, anxiety, and severe withdrawal.”
Co-first author Celsey St. Onge notes that the stronger response in females aligns with clinical observations that women are more prone to autoimmune and hyper-inflammatory conditions, pointing to sex-specific biology as an important consideration in developing addiction therapies. The team cautions that more research is needed to fully disentangle biological sex effects from behavioral differences, since female mice in the study also consumed more alcohol than males.
To connect animal findings to human biology, researchers examined postmortem brain tissue from 30 people with AUD and 30 healthy controls. They found 377 genes differentially expressed in AUD, with IL-6 and other inflammation-related genes among the most upregulated—supporting a translational link between neuroinflammation and alcohol dependence.
Roberto’s lab has previously linked other immune proteins to withdrawal symptoms and explored anti-inflammatory approaches for AUD. Together, these studies support a broader shift in how scientists and clinicians view AUD: as a disorder with substantial neuroimmune components that can be targeted therapeutically.
Funding:
This research was supported by the National Institute on Alcohol Abuse and Alcoholism (AA013498, AA017447, AA027700, P60 AA006420, AA029841, AA012404, U01AA020926, R01AA025996, K99AA031718, T32AA007456, U01AA029965, P60AA010760 and R01AA029486), the National Institute on Drug Abuse (R21DA060442), the Schimmel Family Chair, a VA Merit Review Award (I01BX001819), and facilities and resources at the Portland VA Health Care System.
Key Questions Answered:
A: Rheumatoid arthritis treatments block IL-6 signaling because IL-6 drives inflammation in autoimmune disease. Cells in the brain also produce IL-6. The study found that chronic alcohol use elevates IL-6 in the central amygdala, where it disrupts inhibitory GABA signaling. An IL-6 receptor antibody acts as a molecular shield, preventing IL-6 from altering brain circuits and thereby addressing a core neuroimmune mechanism behind compulsive drinking.
A: GABA is the neurotransmitter that dampens neuronal activity. Chronic alcohol raises IL-6 in the central amygdala, which weakens GABAergic inhibition. Without this brake, neurons become over-excited, producing the mental agitation, intense cravings, anxiety, and withdrawal that perpetuate the cycle of AUD.
A: Females are more susceptible to autoimmune and hyper-inflammatory conditions, a pattern seen in human medicine. The study’s female-specific response suggests AUD may follow different inflammatory pathways by sex. Further research is needed to separate biological sex effects from behavioral variables, but these results underscore the importance of personalized, sex-specific approaches to addiction treatment.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was provided by staff writers.
About this neuropharmacology and AUD research news
Author: Press Office
Source: Scripps Research
Contact: Press Office – Scripps Research
Image: Credit: Neuroscience News
Original Research: Open access. “Translational evidence for increased central amygdala IL-6 activity in alcohol dependence” by Celsey M. St. Onge et al., Journal of Neuroinflammation. DOI: 10.1186/s12974-026-03868-2
Abstract
Translational evidence for increased central amygdala IL-6 activity in alcohol dependence
Alcohol Use Disorder is common worldwide, yet effective treatments are limited. Growing evidence links dysregulated immune signaling in the brain to AUD pathophysiology. Pro-inflammatory pathways such as IL-6 may bridge synaptic dysfunction and the motivational changes seen in dependence.
Using a translational approach and a validated model of chronic alcohol intake, the study examined IL-6 signaling in the central amygdala at the cell-type level. The researchers show that chronic alcohol recruits IL-6–related pathways via astrocytes, neurons, and microglia, and that IL-6 inhibits central amygdala GABAergic transmission. Systemic administration of an IL-6 receptor antibody reduced alcohol drinking in alcohol-dependent female mice.
Together, these results support IL-6 inhibition as a novel neuroimmune-targeted strategy to reduce excessive drinking in the context of AUD.